The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $1.28 in the prior trading day, Karyopharm Therapeutics Inc (NASDAQ: KPTI) closed at $1.17, down -8.59%. In other words, the price has decreased by -$8.59 from its previous closing price. On the day, 1.44 million shares were traded. KPTI stock price reached its highest trading level at $1.305 during the session, while it also had its lowest trading level at $1.13.
Ratios:
Our goal is to gain a better understanding of KPTI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on January 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $8.
On November 04, 2022, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $7 to $10.
JP Morgan Upgraded its Underweight to Neutral on February 09, 2022, while the target price for the stock was maintained at $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 04 ’24 when Paulson Richard A. sold 3,563 shares for $1.29 per share. The transaction valued at 4,596 led to the insider holds 1,157,273 shares of the business.
Paulson Richard A. sold 3,573 shares of KPTI for $4,645 on Mar 05 ’24. The President and CEO now owns 1,160,836 shares after completing the transaction at $1.30 per share. On Mar 01 ’24, another insider, Paulson Richard A., who serves as the President and CEO of the company, sold 19,374 shares for $1.20 each. As a result, the insider received 23,249 and left with 1,164,409 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KPTI now has a Market Capitalization of 134628384 and an Enterprise Value of 252680480. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.93. Its current Enterprise Value per Revenue stands at 1.73 whereas that against EBITDA is -1.959.
Stock Price History:
The Beta on a monthly basis for KPTI is 0.14, which has changed by -0.71393645 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, KPTI has reached a high of $4.30, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -13.29%, while the 200-Day Moving Average is calculated to be -2.00%.
Shares Statistics:
The stock has traded on average 1.76M shares per day over the past 3-months and 1248270 shares per day over the last 10 days, according to various share statistics. A total of 114.92M shares are outstanding, with a floating share count of 107.03M. Insiders hold about 8.11% of the company’s shares, while institutions hold 65.67% stake in the company. Shares short for KPTI as of 1711584000 were 22947206 with a Short Ratio of 13.01, compared to 1709164800 on 23438591. Therefore, it implies a Short% of Shares Outstanding of 22947206 and a Short% of Float of 20.29.
Earnings Estimates
Karyopharm Therapeutics Inc (KPTI) is currently under the scrutiny of 7 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.33 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.37, while EPS last year was -$0.3. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.09 and -$1.33 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is -$1.01, with 7 analysts recommending between -$0.77 and -$1.27.
Revenue Estimates
6 analysts predict $34.47M in revenue for the current quarter. It ranges from a high estimate of $38.36M to a low estimate of $31.7M. As of the current estimate, Karyopharm Therapeutics Inc’s year-ago sales were $36.6M, an estimated decrease of -5.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $36.42M, a decrease of -3.10% over than the figure of -$5.80% in the same quarter last year. There is a high estimate of $39.4M for the next quarter, whereas the lowest estimate is $34.6M.
A total of 6 analysts have provided revenue estimates for KPTI’s current fiscal year. The highest revenue estimate was $150.84M, while the lowest revenue estimate was $142.44M, resulting in an average revenue estimate of $146.52M. In the same quarter a year ago, actual revenue was $146.03M, up 0.30% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $164.74M in the next fiscal year. The high estimate is $209.72M and the low estimate is $130.2M. The average revenue growth estimate for next year is up 12.40% from the average revenue estimate for this year.
